People | September 20, 2024
Dr. Girish Budhrani recognised with ACOIN Gujarat Chapter Oration
ACOIN has recognized Dr. Budhrani's exceptional work in promoting community and clinical ophthalmology
ACOIN has recognized Dr. Budhrani's exceptional work in promoting community and clinical ophthalmology
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Increases efficiency by 70% compared to stainless steel or glass manufacturing methods
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
Subscribe To Our Newsletter & Stay Updated
